title: Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
abstract: Based upon phase I and II studies of deferoxamine alone and in combination with cytotoxic agents cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT), we initiated a single arm multicentre trial in 1992 for advanced neuroblastoma. 57 of 65 patients who entered the trial were evaluable. Following 4 courses of the D-CECaT, almost all the patients underwent surgery. Toxicity was moderate and mainly reversible myelosuppression. The post-surgically defined responses in stage 3 high risk, stage 4 moderate risk and stage 4 high risk patients included 24 complete responses, 26 partial responses, and 3 minor responses, and 4 patients had progressive disease. These patients are being followed to determine the impact of this programme on their overall survival.
authors.affiliation: Ospedale Bambino Gesù, Servizio di Oncologia, Roma, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Donfrancesco
authors.forename: B
authors.initials: B
authors.lastname: De Bernardi
authors.forename: M
authors.initials: M
authors.lastname: Carli
authors.forename: A
authors.initials: A
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Nigro
authors.forename: L
authors.initials: L
authors.lastname: De Sio
authors.forename: F
authors.initials: F
authors.lastname: Casale
authors.forename: S
authors.initials: S
authors.lastname: Bagnulo
authors.forename: L
authors.initials: L
authors.lastname: Helson
authors.forename: G
authors.initials: G
authors.lastname: Deb
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007223:Infant; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012307:Risk Factors; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D003676:Deferoxamine